v3.25.4
Segment and Geographic Area Information
 12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Segment and Geographic Area Information Segment and Geographic Area Information
AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as Chief Operating Decision Maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.
The CODM regularly reviews net revenues, net earnings and significant segment expenses and uses net earnings as its principal measure of segment profit or loss. Net earnings and significant segment expenses reviewed by CODM are reported on the consolidated statement of earnings for the years ended December 31, 2025, 2024 and 2023. The CODM uses net earnings as its principal measure of segment profit or loss to compare past financial performance with current performance and analyze underlying business performance and trends. The CODM does not use segment assets to make decisions regarding resources; therefore, the total asset disclosure has not been included.
Substantially all of AbbVie's pharmaceutical product net revenues in the United States are to three wholesalers. Outside the United States, products are sold primarily to health care providers or through distributors, depending on the market served. The following tables detail AbbVie's worldwide net revenues:
years ended December 31 (in millions)202520242023
Immunology
SkyriziUnited States$15,202 $10,086 $6,753 
International2,360 1,632 1,010 
Total$17,562 $11,718 $7,763 
RinvoqUnited States$5,940 $4,259 $2,824 
International2,364 1,712 1,145 
Total$8,304 $5,971 $3,969 
HumiraUnited States$3,062 $7,142 $12,160 
International1,478 1,851 2,244 
Total$4,540 $8,993 $14,404 
Neuroscience
Vraylar
United States$3,612 $3,260 $2,755 
International9 7 4 
Total$3,621 $3,267 $2,759 
Botox Therapeutic
United States$3,151 $2,718 $2,476 
International618 565 515 
Total$3,769 $3,283 $2,991 
Ubrelvy
United States$1,239 $981 $803 
International32 25 12 
Total$1,271 $1,006 $815 
Qulipta
United States$906 $628 $405 
International130 30 3 
Total$1,036 $658 $408 
Vyalev
United States$167 $1 $— 
International315 98 3 
Total$482 $99 $3 
DuodopaUnited States$73 $96 $97 
International308 351 371 
Total$381 $447 $468 
years ended December 31 (in millions)202520242023
Other Neuroscience
United States$192 $223 $254 
International15 16 19 
Total$207 $239 $273 
Oncology
ImbruvicaUnited States$2,048 $2,448 $2,665 
Collaboration revenues821 899 931 
Total$2,869 $3,347 $3,596 
VenclextaUnited States$1,306 $1,234 $1,087 
International1,486 1,349 1,201 
Total$2,792 $2,583 $2,288 
ElahereUnited States$607 $477 $— 
International83 2 — 
Total$690 $479 $— 
Epkinly
Collaboration revenues
$181 $118 $28 
International90 28 3 
Total$271 $146 $31 
Other OncologyUnited States$33 $— $— 
Aesthetics
Botox Cosmetic
United States$1,504 $1,682 $1,670 
International1,098 1,038 1,012 
Total$2,602 $2,720 $2,682 
Juvederm Collection
United States$385 $469 $519 
International608 708 859 
Total$993 $1,177 $1,378 
Other Aesthetics
United States$1,101 $1,118 $1,060 
International164 161 174 
Total$1,265 $1,279 $1,234 
Eye Care
OzurdexUnited States$124 $138 $143 
International369 356 329 
Total$493 $494 $472 
Lumigan/Ganfort
United States$189 $187 $173 
International221 242 259 
Total$410 $429 $432 
Alphagan/Combigan
United States$53 $95 $121 
International144 153 151 
Total$197 $248 $272 
Other Eye Care
United States$588 $644 $815 
International421 427 424 
Total$1,009 $1,071 $1,239 
Other Key Products
MavyretUnited States$635 $595 $659 
International682 716 771 
Total$1,317 $1,311 $1,430 
CreonUnited States$1,512 $1,383 $1,268 
Linzess/Constella
United States$864 $916 $1,073 
International43 38 35 
Total$907 $954 $1,108 
All other$2,627 $3,032 $3,035 
Total net revenues$61,160 $56,334 $54,318 
    Net revenues to external customers by geographic area, based on product shipm
ent destination, were as follows:
years ended December 31 (in millions)202520242023
United States$46,603 $43,029 $41,883 
Germany1,738 1,465 1,266 
Japan1,274 1,122 1,008 
Canada1,222 1,088 1,076 
China1,006 917 950 
France806 776 780 
United Kingdom626 522 417 
Spain609 528 501 
Italy580 511 484 
Brazil478 464 439 
Australia459 463 472 
All other countries5,759 5,449 5,042 
Total net revenues$61,160 $56,334 $54,318 
See the following for additional information about certain income and expenses included in net earnings: intangible assets amortization expense (Note 7), intangible assets impairment expense (Note 7), change in fair value of contingent consideration (Note 11), interest income and expense (Note 3), depreciation expense (Note 2), litigation matters (Note 15), income tax expense (Note 14) and restructuring expense (Note 8).
Long-lived assets, consisting of property and equipment, net, by geographic area were as follows:
as of December 31 (in millions)20252024
United States
$3,404 $3,331 
Europe1,804 1,485 
All other420 318 
Total long-lived assets$5,628 $5,134